AzTrials
AzTrials

Degenerative ArthritisNCT03247023

Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement

An observational study of Degenerative Arthritis and Rheumatoid Arthritis, run by Smith & Nephew, Inc. at 6 sites in 5 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. Read more about this study

Who is it for?
Ages 19 years and older
What is being tested?
Implantation of Integra Cadence Total Ankle System
Type of treatment
Medical device
How many people
65 participants
Where
6 sitesin 5 countries
Study dates
18 Sep 2017to 6 Sep 2023
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patient with ankle arthritis requiring total ankle replacement

Who may be able to join

  • Subjects will be included if he/she:
  • Is > 18 years of age.
  • Is skeletally mature.
  • Qualifies for primary TAR per the surgeon and has a diagnosis of one of the following: primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), or systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis).
  • Is suitable for TAR with CTAS per the study surgeon based on the product indication and having considered deformity, stability, bone quality, soft- tissue envelope, and neurovascular status.
  • Is willing and able to cooperate in the required post-operative therapy.
  • Is willing and able to complete scheduled follow-up visits, evaluations, and questionnaires as described in the Informed Consent or Information Letter and Data Transfer Authorization Form, as applicable.
  • Reads, understands and signs the Ethical Committee approved Informed Consent or Information Letter and Data Transfer Authorization Form, as applicable

Who cannot join

  • Subjects will be excluded from the study if he/she:
  • Is Morbidly Obese (defined by BMI > 40 or BMI of 35 - 40 with significant medical problems caused by or made worse by their weight).
  • Is an active nicotine user (smoking, chewing, smokeless tobacco, patch) and unwilling to cease nicotine use within 1 month prior to surgery, and 2 months post-surgery.
  • Has one of the following conditions, which could compromise the affected limb: ankle arthrodesis with malleolar exeresis, severe neurological (Charcot's Arthropathy) or vascular disease, loss of musculature or neuromuscular compromise.
  • Has an active local/systemic infection that may affect the prosthetic joint or has a recent history of infection.
  • Continues on long-term medication, which may compromise bone stock (e.g. undergoing immunosuppressive therapy, long-term steroids) and is unable to cease medication usage from 3 weeks prior to surgery to 3 weeks post-surgery.
Show all 16Show fewer
  • Has a condition that may impair proper wound healing (e.g., poor soft tissue envelope).
  • Had previous ankle surgery and/or injury that has adversely affected the anklebone stock.
  • Has had or is scheduled to have contralateral TAR surgery.
  • Is pregnant or plans to become pregnant during the follow up period.
  • Has a metabolic disorder or disease that may compromise bone quality (e.g. arthrogryposis etc.), physiological or anatomical anomalies, and/or malignancy/local bone tumors.
  • Has severe avascular necrosis of the talus/tibia.
  • Has inadequate neuromuscular status (e.g., prior paralysis, severe neuropathy).
  • Has a known sensitivity or allergic reaction to one or more of the implanted materials.
  • Is a poor candidate for general anesthesia.
  • Is a prisoner, mentally incompetent or unable to understand what participation in this study entails, a known alcohol or drug abuser, or anticipated to be non- compliant.

Trial locations and contacts

6 sites in 5 countries.

6 sites in 5 countries

Belgium2 sites
  • Universitair Ziekenhuis Gent

    Ghent, 9000

  • Foot and Ankle Institute

    Woluwe-St-Lambert, B-1200

Other trials in Belgium

Canada1 site
  • St. Michael's Hospital

    Toronto, M5C 1R6

Other trials in Canada

France1 site
  • CHRU Tours

    Tours, 37044

Other trials in France

Spain1 site
  • Clinica Nostra Senhora del Remei

    Barcelona, 08024

Other trials in Spain

United Kingdom1 site
  • North Cumbria University Hospitals

    Carlisle, CA2 7HY

Other trials in United Kingdom

About this study

This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), and systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis)

Being tested
Implantation of Integra Cadence Total Ankle System
Medical subject headings
Osteoarthritis, Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Implantation of Integra Cadence Total Ankle SystemDevice

    Primary Ankle Arthroplasty

Study groups in NCT03247023
Study groupRoleWhat they receive
Integra Cadence Total Ankle SystemNot described
Receives: Device: Implantation of Integra Cadence Total Ankle System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Implant Survivorship at 2 Years

    Implant survivorship determined by the percentage of participants with survival of the device. Successful device survival was defined as absence of device removal or revision.

    Measured: 2 years

Secondary outcomes (18)
  1. Implant Survivorship at 5 Years and 10 Years

    Implant survivorship at 5 years and 10 years was determined by the percentage of participants with device survival. Survivorship was measured using a Kaplan-Meier survival estimate with survival defined as absence of device removal or revision.

    Measured: 5 years and 10 years

  2. Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) - Mobility

    The PROMIS - Physical Function and Mobility score consisted of 15 components on a 5-point Likert scale. Responses were combined to produce a score that ranged from 0 to 100 where higher values represented higher mobility (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  3. Foot and Ankle Ability Measure (FAAM) Activities of Daily Living (ADL) Subscale

    The Foot and Ankle Ability Measure (FAAM) Activities of Daily Living (ADL) Subscale scored 21 components on a 5-point Likert scale. Score totals ranged from 0 to 84 and were transformed to percentage scores with 100 representing no dysfunction (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  4. Visual Analogue Scale (VAS) Pain Score: Resting

    A Visual Analogue Scale (VAS) assessment was used to rate ankle pain while resting. The participant would indicate the level of pain by placing a vertical mark on a 100mm scale. Scores ranged from 0 to 100 with higher scores indicating a higher level of pain (i.e., a higher score was a worse outcome).

    Measured: Baseline, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years

  5. Visual Analogue Scale (VAS) Pain Score: Activity

    A Visual Analogue Scale (VAS) assessment was used to rate ankle pain while during activity. The participant would indicate the level of pain by placing a vertical mark on a 100mm scale. Scores ranged from 0 to 100 with higher scores indicating a higher level of pain (i.e., a higher score was a worse outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  6. Short Form-36 Version 2 Health Survey (SF-36v2): Physical Functioning

    The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Physical Functioning domain focused on limitations in daily activities like running, climbing stairs, bending, or walking. Scores ranged from 0 to 100 with lower scores indicating greater physical disability (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  7. Short Form-36 Version 2 Health Survey (SF-36v2): Role Limitations Due to Physical Health

    The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Role Limitations Due to Physical Health domain focused on limitations in work or other regular daily activities as a result of their physical health. Scores ranged from 0 to 100 with lower scores indicating greater limitation (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  8. Short Form-36 Version 2 Health Survey (SF-36v2): Role Limitations Due to Emotional Problems

    The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Role Limitations Due to Emotional Problems domain focused on limitations in work or other regular daily activities as a result of any emotional problems such as feeling depressed or anxious. Scores ranged from 0 to 100 with lower scores indicating greater limitation (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  9. Short Form-36 Version 2 Health Survey (SF-36v2): Energy/Fatigue

    The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Energy/Fatigue domain focused on feelings of energy, tiredness, and being worn out over the past four weeks. Scores ranged from 0 to 100 with lower scores indicating less energy and more fatigue (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  10. Short Form-36 Version 2 Health Survey (SF-36v2): Emotional Well-being

    The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Emotional Well-being domain focused on feelings of their mental health over the past four weeks. Scores ranged from 0 to 100 with lower scores indicating poor emotional well-being (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  11. Short Form-36 Version 2 Health Survey (SF-36v2): Social Functioning

    The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Social Functioning domain focused on how physical health or emotional problems interfered with their social activities (like visiting with friends, relatives, etc.). Scores ranged from 0 to 100 with lower scores indicating greater disfunction (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  12. Short Form-36 Version 2 Health Survey (SF-36v2): Pain

    The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Pain domain focused on how much pain affected daily activities over the last four weeks. Scores ranged from 0 to 100 with lower scores indicating more pain (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  13. Short Form-36 Version 2 Health Survey (SF-36v2): General Health

    The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The General Health domain focused on perception of overall health and health change over time. Scores ranged from 0 to 100 with lower scores indicating worse health (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  14. Short Form-36 Version 2 Health Survey (SF-36v2): Physical Component Score

    The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Physical Component score combined scores from the Physical Functioning, Role Limitations Due to Physical Health, Pain, and General Health domains. Scores ranged from 0 to 100 with lower scores indicating worse physical health (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  15. Short Form-36 Version 2 Health Survey (SF-36v2): Mental Component Score

    The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Physical Component score combined scores from the Role Limitations Due to Emotional Problems, Energy/Fatigue, Emotional Well-being, and Social Functioning domains. Scores ranged from 0 to 100 with lower scores indicating worse mental health (i.e., a higher score was a better outcome).

    Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years

  16. Radiographic Success

    The number of participants with radiographic success were categorized as either 'Fail' or 'Success'. Success was defined as absence of implant radiolucency, subsidence, tilting, and/or migration with failure specifically defined as occurring if:

    1. ≥3 of the 20 radiolucency zones had >4mm in width, OR
    2. device tilting = present, OR
    3. device subsidence (tibial OR talar) = >4mm, OR
    4. device migration (tibial OR talar) = >4mm

    Measured: 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years

  17. Radiographic Assessment: Ankle Dorsiflexion and Plantarflexion Range of Motion

    Range of motion measurements for ankle dorsiflexion and ankle plantarflexion in degrees were derived from radiographs in positions of maximum plantarflexion and dorsiflexion.

    Measured: Baseline, 1 year, 2 years

  18. Radiographic Assessment: Tibiotalar Range of Motion

    Range of motion measurements were derived from radiographs in positions of maximum plantarflexion and dorsiflexion. Tibiotalar range of motion in degrees was calculated as the difference between the ankle dorsiflexion and ankle plantarflexion angles.

    Measured: Baseline, 1 year, 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Aug 2017
  2. Study start18 Sep 2017
  3. Primary completion6 Sep 2023
  4. Study completion6 Sep 2023

Why it stopped: Sponsor decision not related to safety

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
65 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03247023
Sponsor's protocol ID
T-CTAS-002
Status last verified
Dec 2024
First submitted
8 Aug 2017
Last updated
22 Jun 2026
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Degenerative Arthritis and Rheumatoid Arthritis, run by Smith & Nephew, Inc. at 6 sites in 5 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in Belgium, Canada, France, Spain, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Jun 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Implant Survivorship at 2 Years (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in